Quievrain

Human papillomavirus (HPV) infection is very common and often causes warts in people of all ages. This study evaluates the effectiveness of 2LVERU4 JUNIOR and 2LVERU4 treatments compared to a placebo in helping warts disappear. The trial aims to compare how well these treatments work by the end of a 6-month period, focusing on common, flat, and plantar warts caused by HPV. It is a phase 4, randomized, placebo-controlled, double-blind study involving patients aged 3 years and older. Participants will be assigned to one of two groups: one receiving 2LVERU4 JUNIOR or 2LVERU4 capsules, and the other receiving placebo capsules. Each participant will take one capsule daily, 15 to 30 minutes before breakfast on an empty stomach, following a sequence of capsules numbered 1 through 10, repeated continuously for 6 months. After the treatment phase, there is a 3-month follow-up period to monitor results and any possible recurrence of warts. During the study, patients will be monitored for wart disappearance, defined by normal skin color, texture, and touch at the wart site. Assessments will take place at 4 and 6 months after starting treatment, with additional evaluation of wart recurrence 3 months after treatment ends. Researchers will also compare pain levels related to warts and monitor safety throughout the study. The total study duration can last up to 45 months, including 36 months for patient enrollment and 9 months for follow-up.